Drug Trial Radar · NCT07716618
A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD)
Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
320
Planned (sponsor's estimate)
Start
Jan 17, 2025
Primary completion
May 27, 2026
Study completion Aug 31, 2026
Sponsor
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Salubris (Suzhou) Pharmaceutical Co., Ltd.
- First posted
- Jul 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, double-blind, placebo-controlled, parallel-design clinical trial designed to investigate the efficacy and safety of different doses of sal0120 tablets in patients with CKD.
Conditions
- Chronic Kidney Disease
Interventions
SAL0120 1mgDrug
SAL0120 1mg
SAL0120 2mgDrug
SAL0120 2mg
SAL0120 4mgDrug
SAL0120 4mg
PlaceboDrug
placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The baseline relative change in UACR;The change from baseline in UACR across SAL0120 dose groupsTime frame: at 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.